Prosecution Insights
Prosecution Insights
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEITMEIER, KENDALL NICOLE | 1 | 63.9% | +41.7% |
| SHIAO, REI TSANG | 1 | 79.8% | -33.7% |
| HASTINGS, ALISON AZAR | 1 | 63.3% | +40.3% |
| AULAKH, CHARANJIT | 1 | 80.8% | -15.2% |
| BAUER, NICOLA MARIA | 1 | 57.4% | +48.1% |
| ENGLISH, CONNOR KENNEDY | 1 | 55.8% | +54.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | AULAKH, CHARANJIT | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18134971 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | BAUER, NICOLA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18797261 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | HEITMEIER, KENDALL NICOLE | — |
| 18576933 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | HASTINGS, ALISON AZAR | — |
| 18134971 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | BAUER, NICOLA MARIA | — |
| 17771204 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | ENGLISH, CONNOR KENNEDY | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1627 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18797261 | MORPHIC FORMS OF CFT7455 AND METHODS OF MANUFACTURE THEREOF | HEITMEIER, KENDALL NICOLE | — | §112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18774801 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | SHIAO, REI TSANG | — | DP | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18576933 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | HASTINGS, ALISON AZAR | 1627 | §103 | Final Rejection | — | Pending | Jan 05, 2024 |
| 18534395 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | AULAKH, CHARANJIT | 1621 | DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18134971 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | BAUER, NICOLA MARIA | 1621 | §103§112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 17771204 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Final Rejection | — | Pending | Apr 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial